Positive control lysate for AlphaLISA™ SureFire® Ultra™ Multiplex Human Phospho-CDK1 (Tyr15)/Total CDK1 Detection Kit.
For research use only. Not for use in diagnostic procedures. All products to be used in accordance with applicable laws and regulations including without limitation, consumption and disposal requirements under European REACH regulations (EC 1907/2006).
Feature | Specification |
---|---|
Application | Cell Signaling |
Positive control lysate for AlphaLISA™ SureFire® Ultra™ Multiplex Human Phospho-CDK1 (Tyr15)/Total CDK1 Detection Kit.
For research use only. Not for use in diagnostic procedures. All products to be used in accordance with applicable laws and regulations including without limitation, consumption and disposal requirements under European REACH regulations (EC 1907/2006).
Positive Control Lysate prepared from HEK293 cells, cultured to confluence in T175 flasks in 10% FBS containing medium and lysed in 10 mL of SureFire Ultra Lysis Buffer.
Application |
Cell Signaling
|
---|---|
Automation Compatible |
Yes
|
Brand |
AlphaLISA SureFire Ultra Multiplex
|
Detection Modality |
Alpha
|
Lysis Buffer Compatibility |
Lysis Buffer
|
Molecular Modification |
Phosphorylation
|
Product Group |
Control Lysate
|
Shipping Conditions |
Shipped in Blue Ice
|
Target |
CDK1
|
Target Class |
Phosphoproteins
|
Target Species |
Human
|
Technology |
Alpha
|
Therapeutic Area |
Oncology
|
Unit Size |
1 Vial
|
Are you looking for resources, click on the resource type to explore further.
This guide outlines further possible optimization of cellular and immunoassay parameters to ensure the best possible results are...
The AlphaPlex™ reagent system was designed to enable fast and easy transition from well-established AlphaLISA™ assays to...
Discover Alpha SureFire® Ultra™ assays, the no-wash cellular kinase assays leveraging Revvity's exclusive bead-based technology...
Now you can quantify multiple analytes in a single well for faster and more accurate results, even with low sample volumes
We are here to answer your questions.